Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms.

ABSTRACT:

Background

Mesenchymal stem cells (MSCs) possess powerful immunomodulatory ability. This study aimed to assess the efficacy and safety of human umbilical cord-derived mesenchymal stem cells (UMSCs) in patients with ulcerative colitis (UC) and to explore the potential mechanisms.

Methods

This prospective, self-controlled clinical study was conducted at Henan Provincial People's Hospital. Patients with moderate-to-severe active UC, unresponsive to traditional drugs were continuously enrolled from September 2018 to March 2023. UMSCs were administered intravenously monthly for two months at a cell dosage of 1 × 10⁶ per kg. The primary outcome was a clinical response at 2 months. The levels of cytokines and progerin in the plasma of the patients were analyzed using enz

SUBMITTER: Jiang X 

PROVIDER: S-EPMC11368034 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature